Literature DB >> 16454535

Short-term chloral hydrate administration and cancer in humans.

Tmirah Haselkorn1, Alice S Whittemore, Natalia Udaltsova, Gary D Friedman.   

Abstract

OBJECTIVE: Chloral hydrate, used as a hypnosedative in adults and children, has been shown to be genotoxic and carcinogenic in animal studies. We investigated the potential causal association between chloral hydrate exposure and cancer risk in humans.
METHODS: Cancer incidence was previously determined via biennial screening analyses of the 215 most commonly used drugs between 1976 and 1998 for a cohort of 143,574 outpatients at Kaiser Permanente who had prescriptions filled between 1969 and 1973. Among users of chloral hydrate, statistically significant elevations in standardised morbidity ratios were observed during various years for cancer at five anatomical sites, including the lung, stomach, prostate, skin melanoma and mouth floor. In this analysis, these associations were investigated using: (i) a dose-response analysis among exposed subjects; and (ii) a two-stage design with exposed and non-exposed persons.
RESULTS: There was evidence of an increasing risk of prostate cancer with increasing number of dispensings of chloral hydrate, which persisted after controlling for benign prostatic hypertrophy, vasectomy and obesity; however, the trend was not statistically significant. There was no evidence of a dose-response relationship between chloral hydrate and risk of any of the other four cancers. In the two-stage design, analyses comparing exposed and unexposed subjects showed no increased risk of cancer after controlling for confounding variables; however, the data were suggestive for prostate cancer, where the increased risk associated with chloral hydrate exposure after adjustment for confounding variables persisted. No dose-response relationship was seen for any of the other four cancer sites.
CONCLUSIONS: To our knowledge, this is the first study to examine the relationship between chloral hydrate exposure and cancer risk in humans. There was no persuasive evidence to support a causal relationship between chloral hydrate exposure in humans and the development of cancer. However, statistical power was low for weak associations, particularly for some of the individual cancer sites. Although animal data using much higher doses of chloral hydrate have demonstrated its genotoxicity and carcinogenicity, the effects of chloral hydrate in humans are still uncertain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16454535     DOI: 10.2165/00002018-200629010-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  29 in total

1.  NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.

Authors:  F A Beland
Journal:  Toxic Rep Ser       Date:  1999-08

2.  Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up.

Authors:  J V Selby; G D Friedman; B H Fireman
Journal:  Cancer Res       Date:  1989-10-15       Impact factor: 12.701

3.  A two stage design for the study of the relationship between a rare exposure and a rare disease.

Authors:  J E White
Journal:  Am J Epidemiol       Date:  1982-01       Impact factor: 4.897

Review 4.  Overdose with chloral hydrate: a pharmacological and therapeutic review.

Authors:  S R Graham; R O Day; R Lee; G W Fulde
Journal:  Med J Aust       Date:  1988 Dec 5-19       Impact factor: 7.738

5.  Studies on the mutagenic and carcinogenic potential of chloral hydrate.

Authors:  J Leuschner; N Beuscher
Journal:  Arzneimittelforschung       Date:  1998-10

Review 6.  Have animal data been used inappropriately to estimate risks to humans from environmental trichloroethylene?

Authors:  A D Steinberg; J M DeSesso
Journal:  Regul Toxicol Pharmacol       Date:  1993-10       Impact factor: 3.271

7.  Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines.

Authors:  Ruth L Stephen; Mattias C U Gustafsson; Morag Jarvis; Roger Tatoud; Barry R Marshall; Deborah Knight; Ewa Ehrenborg; Adrian L Harris; C Roland Wolf; Colin N A Palmer
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

8.  Dietary controlled carcinogenicity study of chloral hydrate in male B6C3F1 mice.

Authors:  Julian E A Leakey; John E Seng; John R Latendresse; Nursreen Hussain; Laura J Allen; William T Allaben
Journal:  Toxicol Appl Pharmacol       Date:  2003-12-01       Impact factor: 4.219

9.  Toxicokinetics of chloral hydrate in ad libitum-fed, dietary-controlled, and calorically restricted male B6C3F1 mice following short-term exposure.

Authors:  John E Seng; Nalini Agrawal; Elizabeth T M Horsley; Tatiana I Leakey; Erin M Scherer; Shijun Xia; William T Allaben; Julian E A Leakey
Journal:  Toxicol Appl Pharmacol       Date:  2003-12-01       Impact factor: 4.219

10.  Further studies on incomplete carcinogenesis: triethylene melamine (T.E.M.), 1,2-benzanthracene and beta-propiolactone, as initiators of skin tumour formation in the mouse.

Authors:  F J ROE; M H SALAMAN
Journal:  Br J Cancer       Date:  1955-03       Impact factor: 7.640

View more
  9 in total

1.  Chloral hydrate sedation in radiology: retrospective audit of reduced dose.

Authors:  Jennifer Bracken; Ingrid Heaslip; Stephanie Ryan
Journal:  Pediatr Radiol       Date:  2012-01-13

2.  Chloral hydrate, chloral hydrate--promethazine and chloral hydrate -hydroxyzine efficacy in electroencephalography sedation.

Authors:  Razieh Fallah; Ali Alaei; Sedighah Akhavan Karbasi; Ahmad Shajari
Journal:  Indian J Pediatr       Date:  2014-01-21       Impact factor: 1.967

Review 3.  Intranasal Dexmedetomidine for Procedural Sedation in Children, a Suitable Alternative to Chloral Hydrate.

Authors:  Giorgio Cozzi; Stefania Norbedo; Egidio Barbi
Journal:  Paediatr Drugs       Date:  2017-04       Impact factor: 3.022

Review 4.  Chloral hydrate as a sedating agent for neurodiagnostic procedures in children.

Authors:  Choong Yi Fong; Chee Geap Tay; Lai Choo Ong; Nai Ming Lai
Journal:  Cochrane Database Syst Rev       Date:  2017-11-03

Review 5.  Chloral hydrate as a sedating agent for neurodiagnostic procedures in children.

Authors:  Choong Yi Fong; Wei Kang Lim; Limin Li; Nai Ming Lai
Journal:  Cochrane Database Syst Rev       Date:  2021-08-16

6.  Factors affecting successful use of intranasal dexmedetomidine: a cohort study from a national paediatrics tertiary centre.

Authors:  Lijia Fan; Yinghao Lim; Gloria Songmei Wong; Ryan Taylor
Journal:  Transl Pediatr       Date:  2021-04

Review 7.  Conscious Sedation: Emerging Trends in Pediatric Dentistry.

Authors:  Joginder Pal Attri; Radhe Sharan; Vega Makkar; Kewal Krishan Gupta; Ranjana Khetarpal; Amar Parkash Kataria
Journal:  Anesth Essays Res       Date:  2017 Apr-Jun

8.  Efficacy of Chloral Hydrate and Promethazine for Sedation during Electroencephalography in Children; a Randomised Clinical Trial.

Authors:  Fallah Razieh; Jalili Sharam; Golestan Motahhareh; Akhavan Karbasi Sedighah; Jarahzadeh Mohammad-Hosein
Journal:  Iran J Pediatr       Date:  2013-02       Impact factor: 0.364

9.  Efficacy of chloral hydrate-hydroxyzine and chloral hydrate-midazolam in pediatric magnetic resonance imaging sedation.

Authors:  Razieh Fallah; Nafiseh Fadavi; Shekofah Behdad; Mahmoud Fallah Tafti
Journal:  Iran J Child Neurol       Date:  2014
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.